Amgen (AMGN) vs AstraZeneca (AZN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Amgen (AMGN) has outperformed AstraZeneca (AZN) over the past year, gaining 38.3% versus a loss of 7.0%. Over five years, AMGN leads with a +96.0% price change compared with +31.8% for AZN. AstraZeneca is the larger company by market cap ($246.25 billion vs $220.28 billion), about 1.1 times the size, while Amgen is growing revenue faster (+10.0% vs +8.6%).
On valuation, AstraZeneca trades at a lower forward P/E (13.7x vs 16.6x for Amgen). Amgen offers the higher dividend yield (2.41% vs 2.03%). Amgen converts more of its revenue into profit, with a net margin of 21.0% versus 17.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMGN | AZN |
|---|---|---|
| Share price | $407.44 | $158.78 |
| Market cap | $220.28B | $246.25B |
| 1-day change | -1.37% | -0.84% |
| YTD return | +24.48% | -13.64% |
| 1-year return | +38.29% | -7.02% |
| 5-year return | +96.04% | +31.83% |
| P/E ratio (TTM) | 25.31 | 23.73 |
| Forward P/E | 16.64 | 13.73 |
| EPS (TTM) | $16.10 | $6.69 |
| Dividend yield | 2.41% | 2.03% |
| Annual dividend | $9.80 | $3.23 |
| Revenue (latest FY) | $36.75B | $58.74B |
| Revenue growth (YoY) | +9.95% | +8.63% |
| Net income (latest FY) | $7.71B | $10.22B |
| Gross margin | 67.25% | 81.90% |
| Operating margin | 24.71% | 23.40% |
| Net margin | 20.98% | 17.41% |
| 52-week high | $447.03 | $212.71 |
| 52-week low | $288.00 | $153.41 |
| Distance from 52-week high | -8.86% | -25.35% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | -3.92% | +33.11% |
| Average volume | 2.73M | 3.42M |
| Shares outstanding | 540.63M | 1.55B |
| Employees | 31,500 | 96,100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AMGN has outperformed AZN by 45.3 percentage points over the past year.
About Amgen
AMGN stock →Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 31,500 employees
About AstraZeneca
AZN stock →AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI.
Health Care · Biotechnology: Pharmaceutical Preparations · 96,100 employees
AMGN vs AZN FAQ
Which is bigger, Amgen or AstraZeneca?
AstraZeneca (AZN) is larger, with a market capitalization of $246.25B compared with $220.28B for Amgen (AMGN).
Which stock has performed better over the past year, AMGN or AZN?
AMGN returned +38.29% over the past 12 months, compared with -7.02% for AZN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, AMGN or AZN?
AZN has the lower trailing P/E at 23.7, versus 25.3 for AMGN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Amgen or AstraZeneca?
Amgen has the higher yield at 2.41%, compared with 2.03% for AstraZeneca.
Are Amgen and AstraZeneca in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Amgen and Biotechnology: Pharmaceutical Preparations for AstraZeneca.